Today, monoclonal antibodies are the key anti- TNF-α drugs approved forclinical use; however, they cause adverse events such as increasedsusceptibility to infections, as well as the development of demyelinatingdiseases and malignancies [41]. This evidence concerns the gene TNF and infection.